drugset
drugset / Trial / NCT01160107

Revlimid And Prednisone Followed By Revlimid, Melphalan And Prednisone In Multiple Myeloma Patients

NCT01160107 ↗

Phase 2 Completed 46 enrolled Fondazione EMN Italy Onlus
NaSingle-groupOpen-labelTreatment

Summary

This study will determine whether the association of Revlimid and Prednisone (RP) as induction treatment followed by Revlimid, Melphalan and Prednisone (MPR) as consolidation treatment is safe and induce a significant rate of PR (and CR) in newly diagnosed elderly MM patients.

Timeline

Start
2008-07
Primary completion
2012-08
Completion
2022-12-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenalidomide Other / unclassified 10 mg Oral
Subject Lenalidomide Other / unclassified 15 mg Oral
Subject Lenalidomide Other / unclassified 20 mg Oral
Subject Lenalidomide Other / unclassified 25 mg Oral
Subject Melphalan Small molecule 2 mg Oral
Subject Prednisone Other / unclassified 25 mg Oral
Subject Prednisone Other / unclassified 50 mg Oral

Indications

plasma cell myeloma